Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.49 |
| ▸ | TNF | P01375 | 3/20 | 0.49 |
| ▸ | IL1B | P01584 | 3/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23534330 | 0.86 | CRBN (0.49) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24132311 | 0.85 | CRBN (0.47) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL23561466 | 0.84 | CRBN (0.46) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21751090 | 0.82 | CRBN (0.52) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29362393 | 0.81 | CRBN (0.62) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21751117 | 0.81 | CRBN (0.62) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24132969 | 0.80 | CRBN (0.47) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24132589 | 0.80 | CRBN (0.45) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24132599 | 0.80 | CRBN (0.47) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL21751113 | 0.80 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039273-A | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-110621664-B | Novel piperidine-2, 6-dione derivatives and uses thereof | 韩国化学研究院 | 2023-08-01 | — | — | CN | claimed |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4076464-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | Orionis Biosciences, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| CN-115038448-A | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2022-09-09 | — | — | CN | claimed |
| EP-3623366-B9 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2022-06-15 | — | — | EP | claimed |
| EP-3623366-B1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2022-01-19 | — | — | EP | claimed |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-12-07 | — | — | US | claimed |
| WO-2021126973-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| EP-3623366-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2020-03-18 | — | — | EP | claimed |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2020-02-27 | — | — | US | claimed |
| CN-119039273-A | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-119039271-A | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-119039272-A | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-115038448-B | Compounds that modulate protein recruitment and/or degradation | 奥里尼斯生物科学股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2020162725-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2020-08-13 | — | — | WO | disclosed |
| EP-3623366-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2020-03-18 | — | — | EP | disclosed |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2020-02-27 | — | — | US | disclosed |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2020-02-27 | — | — | US | disclosed |
| CN-110621664-A | Novel piperidine-2, 6-dione derivatives and uses thereof | 韩国化学研究院 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | CRBN, STUB1, ADRM1 | CRBN 1/4885DDB1 171/4885IKZF3 463/4885 |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | CRBN, PDCD11, CD47 | CRBN 1/4885DDB1 153/4885IKZF3 969/4885 |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | CRBN, PDCD11, CD47 | CRBN 1/4885DDB1 196/4885IKZF3 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.